Mnemonic

Does the drug SWIM? ⁣
🏊 “Is it Safe?” Assesses safety, toxicity, pharmacokinetics, and pharmacodynamics⁣
🏊 “Does it Work?” Assesses treatment efficacy, optimal dosing, and adverse effects.⁣
🏊 “Is it as good or better?” Compares the new treatment to the current standard of care (any Improvement?).⁣
🏊 “Can it stay?” Detects rare or long-term adverse effects (eg, black box warnings). Can result in treatment being withdrawn from Market.⁣

highresdefault_L67113.jpg

  • Phase 0 trial
    • Purpose: Exploratory phase with no therapeutic or diagnostic intent, aimed at gaining insight into pharmacokinetics and pharmacodynamics.
    • Only < ​1% of the therapeutic dose is used.
    • Safety and toxicity are not assessed.
    • Study population: Small sample consisting of either healthy individuals or a population with a disease of interest (∼ 10–15).
    • Study design: Open-label.
  • Phase I trial
    • Purpose: Evaluation of pharmacodynamic and pharmacokinetic properties of the drug, safety, and toxicity.
    • Evaluation of the maximum tolerated dose.
    • Study population: Small number of healthy individuals or patients with a specific disease (∼ 15–30).
    • Study design: Open-label.
  • Phase II trial
    • Purpose: Evaluation of efficacy, optimal dose range, and side effects (especially common and short-term side effects).
    • Study population: Moderate number of patients with a specific disease (∼ 10–100).
    • Study design: Randomized, Controlled, Anonymized.
  • Phase III trial
    • Purpose: Final confirmation of safety and evaluation of efficacy against placebo or the current standard of care.
    • Study population: Randomized control trial with a large number of patients with a specific disease (∼ 100–1000).
    • Study design: Randomized Controlled Trial.
  • Phase IV trial
    • Purpose: Postmarketing surveillance, comparing real-life efficacy to that described in research studies. Safety studies following approval (especially evaluation of rare and long-term side effects).
    • Study population: Large number of patients with a specific disease after drug approval.
    • Study design: Open-label.